Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024

Press Release

Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024

• Focusing resources on the clinical development of Nicox’s lead program NCX 470 in glaucoma
• NCX 470 Denali Phase 3 trial in patients with open-angle glaucoma or ocular hypertension on track to generate topline results in H2 2025
• Objective of securing financing to support clinical development of NCX 470
• Implementing cost reductions and exploring developing other assets through collaborations
• Webcast (in French) to be held on March 18, 2024 at 6:00 pm CET; additional details to follow

March 13, 2024 – release at 7:30 am CET

Sophia Antipolis, France

Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided an update on its corporate and development strategy, in the context of its debt restructuring and the appointment of Gavin Spencer as Chief Executive Officer and announced it will be holding a Webcast (in French) on March 18, 2024 at 6:00 pm CET. Further details on the webcast will be sent shortly.

“Nicox